SB497115
497115/003
Phase 2 small_molecule completed
Quick answer
SB497115 for Thrombocytopaenia is a Phase 2 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Thrombocytopaenia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed